Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Smith MR, et al. Among authors: mohamed af. Eur J Cancer. 2021 Sep;154:138-146. doi: 10.1016/j.ejca.2021.06.010. Epub 2021 Jul 14. Eur J Cancer. 2021. PMID: 34273811 Free article. Clinical Trial.
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M, Shore ND, Smith MR, Tammela TLJ, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Lebret T, Schostak M, Verholen F, Le Berre MA, Srinivasan S, Ortiz J, Mohamed AF, Sarapohja T, Fizazi K. Bögemann M, et al. Among authors: mohamed af. Eur Urol. 2023 Mar;83(3):212-221. doi: 10.1016/j.eururo.2022.07.018. Epub 2022 Sep 9. Eur Urol. 2023. PMID: 36089529 Free article. Clinical Trial.
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022].
Bögemann M, Shore ND, Smith MR, Tammela TLJ, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Lebret T, Schostak M, Verholen F, Le Berre MA, Srinivasan S, Ortiz J, Mohamed AF, Sarapohja T, Fizazi K. Bögemann M, et al. Among authors: mohamed af. Eur Urol. 2023 Feb;83(2):e60. doi: 10.1016/j.eururo.2022.11.018. Epub 2022 Dec 14. Eur Urol. 2023. PMID: 36526492 Free article. No abstract available.
The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer.
Beyer K, MacLennan SJ, Moris L, Lardas M, Mastris K, Hooker G, Greene R, Briers E, Omar MI, Healey J, Tripathee S, Gandaglia G, Venderbos LDF, Smith EJ, Bjorkqvist J, Asiimwe A, Huber J, Roobol MJ, Zong J, Bjartell A, N'Dow J, Briganti A, MacLennan S, Van Hemelrijck M; PIONEER Consortium; EAU; LU; UNISR; Erasmus; UKE; TAU; KCL; EORTC; TTOP; ICHOM; ECPC; ASSOC EISBM; ICL; Hyve; EAPM; PM; WI; UoA; TUD; Fraunhofer; UGOT; Radboud; IHE; Bayer AG; SANOFI; ASTELLAS; SAS; Janssen; IQVIA; eGF-eCancer; AstraZeneca; HelmHoltz. Beyer K, et al. Eur Urol Focus. 2021 Sep;7(5):943-946. doi: 10.1016/j.euf.2021.09.008. Epub 2021 Oct 1. Eur Urol Focus. 2021. PMID: 34602368 Free article.
170 results